Chemotherapy for metastatic colorectal cancer

Drug and Therapeutics Bulletin

Volumn 40, Issue 7, 2002, Pages 49-52

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ATROPINE; CAPECITABINE; CREATININE; CYTOTOXIC AGENT; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLATINUM DERIVATIVE; PRODRUG; RALTITREXED; TEGAFUR; THYMIDYLATE SYNTHASE; URACIL; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; PLATINUM COMPLEX;

ABDOMINAL CRAMP; ALOPECIA; ARTICLE; BLEPHARITIS; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; COLITIS; COLORECTAL CANCER; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TISSUE LEVEL; DYSPNEA; ESOPHAGITIS; GASTRITIS; HAND FOOT SYNDROME; HUMAN; HYPOTENSION; LETHARGY; METASTASIS; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; PARESTHESIA; PHARYNGITIS; QUALITY OF LIFE; SKIN MANIFESTATION; UNITED KINGDOM; COLORECTAL TUMOR; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 0036023023     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2002.40749     Document Type: Article

References (32)

1. Mortality statistics: Review of the Registrar General on deaths by cause, sex and age, in England and Wales, 1999
2. Palliative chemotherapy for advanced colorectal cancer: Systematic review and meta-analysis
3. Metastatic colorectal cancer: Treatment challenges and quality of life
4. Colorectal cancer
5. Survival benefit of chemotherapy in metastatic colorectal cancer: A meta-analysis of randomized controlled trials
6. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
7. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
8. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
9. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: A multicentre randomised trial
10. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
11. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
12. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
13. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
14. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer
15. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer
16. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies
17. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
18. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
19. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable [liver] metastases
20. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
21. Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5FU + LV) in patients with advanced colorectal cancer (ACC): Results of a randomized, multicenter, North American trial
22. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer
23. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
24. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study
25. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
26. UFT plus oral leucovorin: A new oral treatment for colorectal cancer
27. Randomized comparative study of Orzel (oral uracil/tegafur (UFT) plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer
28. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer
29. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma
30. Guidance on the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer
31. Why hasn't the National Institute been 'NICE' to patients with colorectal cancer?
32. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study